In contrast to other GBM-associated surface antigens, such as HER2, EGFRvIII and IL-13Rα2 are unique because they are frequently expressed in GBM cells but are absent or present at very low levels in somatic tissues, reducing the likelihood of on-target, off-tumor toxicity. This evidence concerns the gene ERBB2 and glioblastoma.